Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
G1 Therapeutics Inc's Business Segments
G1 Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 17
Regions Reported
-
G1 Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product95.7%
- License4.3%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 16 | 95.7% |
| License | $ 1 | 4.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of G1 Therapeutics Inc
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies to address significant unmet needs in the treatment of cancer. The company focuses on the discovery, development, and commercialization of small molecule-based therapies that are designed to interfere with the progression of cancer.
G1 Therapeutics was founded in 2008 and is headquartered in Research Triangle Park, North Carolina. The company has established a strong pipeline of investigational oncology products, with a particular emphasis on targeting cyclin-dependent kinases (CDKs) and myeloid cell leukemia (MCL) protein.
One of the key areas of research for G1 Therapeutics is the development of CDK4/6 inhibitors, which have demonstrated significant potential in the treatment of various forms of cancer. CDK4/6 inhibitors work by blocking the activity of specific proteins that control the progression of the cell cycle, thereby preventing the growth and division of cancer cells.
G1 Therapeutics' lead product candidate is trilaciclib (formerly known as G1T28), a CDK4/6 inhibitor that is being developed to improve outcomes in patients undergoing chemotherapy. Trilaciclib has shown promise in preclinical and clinical studies, demonstrating the ability to enhance the anti-tumor effect of chemotherapy while protecting normal cells from chemotherapy-induced damage.
In addition to trilaciclib, G1 Therapeutics is also advancing other CDK4/6 inhibitors, such as lerociclib (formerly known as G1T38) and G1T48, which are being evaluated for the treatment of various types of cancer, including breast, lung, and ovarian cancer. These candidates have shown strong potential in preclinical studies and are currently undergoing clinical trials to assess their safety and efficacy.
Furthermore, G1 Therapeutics is also developing therapies that target the MCL protein, which plays a critical role in the development and progression of certain types of cancer, particularly small cell lung cancer (SCLC). The company's lead MCL inhibitor, G1T48, has exhibited promising anti-tumor activity in preclinical models and is currently being evaluated in clinical trials for SCLC and other malignancies driven by MCL protein.
Apart from its robust drug development pipeline, G1 Therapeutics has also established strategic collaborations with renowned pharmaceutical companies, including Boehringer Ingelheim, Genentech, and AstraZeneca. These collaborations enable G1 Therapeutics to leverage the resources and expertise of these partners to accelerate the clinical development and commercialization of its pipeline candidates.
Overall, G1 Therapeutics Inc is a dynamic and innovative biopharmaceutical company that is dedicated to developing novel therapies to improve the lives of cancer patients. With a strong pipeline of potential breakthrough candidates and strategic collaborations, the company is well-positioned to make a significant impact in the field of oncology.
G1 Therapeutics was founded in 2008 and is headquartered in Research Triangle Park, North Carolina. The company has established a strong pipeline of investigational oncology products, with a particular emphasis on targeting cyclin-dependent kinases (CDKs) and myeloid cell leukemia (MCL) protein.
One of the key areas of research for G1 Therapeutics is the development of CDK4/6 inhibitors, which have demonstrated significant potential in the treatment of various forms of cancer. CDK4/6 inhibitors work by blocking the activity of specific proteins that control the progression of the cell cycle, thereby preventing the growth and division of cancer cells.
G1 Therapeutics' lead product candidate is trilaciclib (formerly known as G1T28), a CDK4/6 inhibitor that is being developed to improve outcomes in patients undergoing chemotherapy. Trilaciclib has shown promise in preclinical and clinical studies, demonstrating the ability to enhance the anti-tumor effect of chemotherapy while protecting normal cells from chemotherapy-induced damage.
In addition to trilaciclib, G1 Therapeutics is also advancing other CDK4/6 inhibitors, such as lerociclib (formerly known as G1T38) and G1T48, which are being evaluated for the treatment of various types of cancer, including breast, lung, and ovarian cancer. These candidates have shown strong potential in preclinical studies and are currently undergoing clinical trials to assess their safety and efficacy.
Furthermore, G1 Therapeutics is also developing therapies that target the MCL protein, which plays a critical role in the development and progression of certain types of cancer, particularly small cell lung cancer (SCLC). The company's lead MCL inhibitor, G1T48, has exhibited promising anti-tumor activity in preclinical models and is currently being evaluated in clinical trials for SCLC and other malignancies driven by MCL protein.
Apart from its robust drug development pipeline, G1 Therapeutics has also established strategic collaborations with renowned pharmaceutical companies, including Boehringer Ingelheim, Genentech, and AstraZeneca. These collaborations enable G1 Therapeutics to leverage the resources and expertise of these partners to accelerate the clinical development and commercialization of its pipeline candidates.
Overall, G1 Therapeutics Inc is a dynamic and innovative biopharmaceutical company that is dedicated to developing novel therapies to improve the lives of cancer patients. With a strong pipeline of potential breakthrough candidates and strategic collaborations, the company is well-positioned to make a significant impact in the field of oncology.
G1 Therapeutics Inc. is a biotechnology company that primarily focuses on the development of innovative therapies for cancer treatment. The company aims to address unmet medical needs in oncology with a strong emphasis on improving outcomes for patients through its various segments, products, and services.
Segments
1. Research and Development (R&D)
- G1 Therapeutics is heavily focused on R&D, dedicating resources towards discovering and developing new drugs. This segment involves extensive preclinical and clinical trials designed to evaluate the safety and efficacy of their therapeutic candidates. The R&D team collaborates with academic institutions and other research organizations to advance their portfolio of drug candidates.
2. Commercialization
- Another key segment of G1 Therapeutics involves the commercialization of its oncology products. This includes marketing strategies, sales, and distribution efforts to ensure that their drugs reach healthcare providers and patients. The commercialization strategy often involves partnerships with larger pharmaceutical companies to leverage their distribution networks and expertise in the oncology market.
3. Regulatory Affairs
- The regulatory affairs segment is crucial for ensuring that the company’s products comply with all necessary regulations and guidelines set by health authorities like the FDA and EMA. This segment focuses on the submission of investigational new drug applications (INDs), new drug applications (NDAs), and monitoring compliance throughout the development process.
Products
1. TriTuzumab (G1T38)
- TriTuzumab is a novel oncology therapeutic that targets the HER2 protein, frequently overexpressed in certain types of breast cancer. The therapy is currently in clinical trials aimed at evaluating its effectiveness and safety in treating patients with HER2-positive cancers.
2. G1T28
- G1T28 is another therapeutic candidate under development that targets specific pathways involved in cancer cell proliferation and resistance to current treatments. This product aims to enhance the efficacy of existing therapies, particularly in advanced-stage cancers.
3. G1T36
- Designed for hematological malignancies, G1T36 is focused on treating conditions like leukemia and lymphoma. The product is in various stages of clinical evaluation, assessing its safety profile and potential benefits for patients with these blood cancers.
Services
1. Clinical Trial Management
- G1 Therapeutics offers comprehensive clinical trial management services, from designing and implementing trials to monitoring and reporting outcomes. This includes regulatory oversight and liaising with clinical sites to ensure compliance with trial protocols.
2. Consulting and Advisory Services
- The company provides consulting services to other biotech firms and research institutions. These services focus on best practices in drug development, regulatory requirements, and commercial strategy for oncology products.
3. Collaborative Partnerships
- G1 Therapeutics actively engages in collaborative partnerships with other pharmaceutical companies and research organizations. These partnerships enable shared resources, data, and expertise, enhancing the development pipeline.
4. Educational Programs
- G1 Therapeutics conducts educational initiatives for healthcare professionals to raise awareness about their products and the importance of oncology research. These programs often include seminars, webinars, and continuing medical education (CME) opportunities.
Through these segments, products, and services, G1 Therapeutics aims to provide innovative solutions to improve cancer treatment outcomes and enhance the quality of life for patients battling various types of cancer. Their commitment to R&D, commercialization, and collaboration positions them as a notable player in the biotechnology and oncology fields.
Segments
1. Research and Development (R&D)
- G1 Therapeutics is heavily focused on R&D, dedicating resources towards discovering and developing new drugs. This segment involves extensive preclinical and clinical trials designed to evaluate the safety and efficacy of their therapeutic candidates. The R&D team collaborates with academic institutions and other research organizations to advance their portfolio of drug candidates.
2. Commercialization
- Another key segment of G1 Therapeutics involves the commercialization of its oncology products. This includes marketing strategies, sales, and distribution efforts to ensure that their drugs reach healthcare providers and patients. The commercialization strategy often involves partnerships with larger pharmaceutical companies to leverage their distribution networks and expertise in the oncology market.
3. Regulatory Affairs
- The regulatory affairs segment is crucial for ensuring that the company’s products comply with all necessary regulations and guidelines set by health authorities like the FDA and EMA. This segment focuses on the submission of investigational new drug applications (INDs), new drug applications (NDAs), and monitoring compliance throughout the development process.
Products
1. TriTuzumab (G1T38)
- TriTuzumab is a novel oncology therapeutic that targets the HER2 protein, frequently overexpressed in certain types of breast cancer. The therapy is currently in clinical trials aimed at evaluating its effectiveness and safety in treating patients with HER2-positive cancers.
2. G1T28
- G1T28 is another therapeutic candidate under development that targets specific pathways involved in cancer cell proliferation and resistance to current treatments. This product aims to enhance the efficacy of existing therapies, particularly in advanced-stage cancers.
3. G1T36
- Designed for hematological malignancies, G1T36 is focused on treating conditions like leukemia and lymphoma. The product is in various stages of clinical evaluation, assessing its safety profile and potential benefits for patients with these blood cancers.
Services
1. Clinical Trial Management
- G1 Therapeutics offers comprehensive clinical trial management services, from designing and implementing trials to monitoring and reporting outcomes. This includes regulatory oversight and liaising with clinical sites to ensure compliance with trial protocols.
2. Consulting and Advisory Services
- The company provides consulting services to other biotech firms and research institutions. These services focus on best practices in drug development, regulatory requirements, and commercial strategy for oncology products.
3. Collaborative Partnerships
- G1 Therapeutics actively engages in collaborative partnerships with other pharmaceutical companies and research organizations. These partnerships enable shared resources, data, and expertise, enhancing the development pipeline.
4. Educational Programs
- G1 Therapeutics conducts educational initiatives for healthcare professionals to raise awareness about their products and the importance of oncology research. These programs often include seminars, webinars, and continuing medical education (CME) opportunities.
Through these segments, products, and services, G1 Therapeutics aims to provide innovative solutions to improve cancer treatment outcomes and enhance the quality of life for patients battling various types of cancer. Their commitment to R&D, commercialization, and collaboration positions them as a notable player in the biotechnology and oncology fields.